FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381377864> ?p ?o ?g. }

• W4381377864 abstract "Background: SGLT2 inhibitors have been shown to slow cardiac and renal disease progression. Currently, there is limited literature on the impact of SGLT2 inhibitors on DR and more specifically DME. Objective: Evaluate the effect of SGLT2 inhibitors on central subfoveal thickness (CST) in patients with T2D and on the need and frequency of intravitreal injections (IVI) for DME. Methods: A retrospective matched cohort study with propensity score matching to reduce confounding and determine treatment effect. Covariates: age, sex, type of DM, last A1c, level of retinopathy, insurance, IVI, Visual Acuity (VA). Treatment: SGLT2i use. Primary Outcome: CST on Optical Coherence Tomography (OCT). Secondary Outcomes: IVI use and frequency for DME. By ICD-10 codes 10,026 patients were found to have diabetes and were seen in 2021 at Retina Associates, LLC Kansas City. Retrospectively screened 1,000 consecutive patient medical records from this cohort and included those with T2D and on an SGLT2i. We excluded those with incomplete records, T1D, and those who had a second diagnosis that could cause macular edema. Results: 321 patients had DR; 280 with T2D of which 71 were on an SGLT2i and included for analysis. Baseline cohort characteristics: mean age (SD): 62.2 yr (11.4); 58.9% were male; 76.1% White, 11.1% Black, 6.8% Hispanic/Latino; 13.2% used tobacco; 75.4% had HTN; last recorded A1C 7.6 (1.6); Visual Acuity in ETDRS letters OD: 74.1 (12.9) OS: 73.8 (14.7); CST OD: 279.9 (56.6) OS: 279.6 (54.7). Comparing CST and the need for IVI to those not on an SGLT2i the CST OD/OS was 280.1 (32)/280.3 (36.3) vs 279.9 (62.8)/279.4 (59.7) and 40.8% vs 36.8% required IVI with a risk ratio of 1.13 and a risk difference of 0.03 and p-value of 0.55 95% CI [-0.07, 0.14]. After Propensity Score Matching: ATE risk difference was 0.04 and a p-value of 0.37 and 95% CI [-0.05, 0.14]. Conclusions: No positive or negative effect on mean CST or difference in the average treatment effect for DME was found for those taking an SGLT2 inhibitor. Disclosure H.Stevens: None. J.M.Breen: None. B.A.Cooper: Advisory Panel; Genentech, Inc., Speaker's Bureau; Regeneron, Optomed." @default.
• W4381377864 created "2023-06-21" @default.
• W4381377864 creator A5025282652 @default.
• W4381377864 creator A5055542255 @default.
• W4381377864 creator A5065878246 @default.
• W4381377864 date "2023-06-20" @default.
• W4381377864 modified "2023-09-25" @default.
• W4381377864 title "500-P: Causal Effect of SGLT2 Inhibition on Diabetes-Related Retinopathy (DR) and Macular Edema (DME)" @default.
• W4381377864 doi "https://doi.org/10.2337/db23-500-p" @default.
• W4381377864 hasPublicationYear "2023" @default.
• W4381377864 type Work @default.
• W4381377864 citedByCount "0" @default.
• W4381377864 crossrefType "journal-article" @default.
• W4381377864 hasAuthorship W4381377864A5025282652 @default.
• W4381377864 hasAuthorship W4381377864A5055542255 @default.
• W4381377864 hasAuthorship W4381377864A5065878246 @default.
• W4381377864 hasConcept C118487528 @default.
• W4381377864 hasConcept C126322002 @default.
• W4381377864 hasConcept C134018914 @default.
• W4381377864 hasConcept C141071460 @default.
• W4381377864 hasConcept C167135981 @default.
• W4381377864 hasConcept C17923572 @default.
• W4381377864 hasConcept C195910791 @default.
• W4381377864 hasConcept C201903717 @default.
• W4381377864 hasConcept C2777180221 @default.
• W4381377864 hasConcept C2778257484 @default.
• W4381377864 hasConcept C2779829184 @default.
• W4381377864 hasConcept C2780347916 @default.
• W4381377864 hasConcept C555293320 @default.
• W4381377864 hasConcept C71924100 @default.
• W4381377864 hasConcept C72563966 @default.
• W4381377864 hasConcept C77350462 @default.
• W4381377864 hasConceptScore W4381377864C118487528 @default.
• W4381377864 hasConceptScore W4381377864C126322002 @default.
• W4381377864 hasConceptScore W4381377864C134018914 @default.
• W4381377864 hasConceptScore W4381377864C141071460 @default.
• W4381377864 hasConceptScore W4381377864C167135981 @default.
• W4381377864 hasConceptScore W4381377864C17923572 @default.
• W4381377864 hasConceptScore W4381377864C195910791 @default.
• W4381377864 hasConceptScore W4381377864C201903717 @default.
• W4381377864 hasConceptScore W4381377864C2777180221 @default.
• W4381377864 hasConceptScore W4381377864C2778257484 @default.
• W4381377864 hasConceptScore W4381377864C2779829184 @default.
• W4381377864 hasConceptScore W4381377864C2780347916 @default.
• W4381377864 hasConceptScore W4381377864C555293320 @default.
• W4381377864 hasConceptScore W4381377864C71924100 @default.
• W4381377864 hasConceptScore W4381377864C72563966 @default.
• W4381377864 hasConceptScore W4381377864C77350462 @default.
• W4381377864 hasIssue "Supplement_1" @default.
• W4381377864 hasLocation W43813778641 @default.
• W4381377864 hasOpenAccess W4381377864 @default.
• W4381377864 hasPrimaryLocation W43813778641 @default.
• W4381377864 hasRelatedWork W1977181510 @default.
• W4381377864 hasRelatedWork W1988341374 @default.
• W4381377864 hasRelatedWork W1990382931 @default.
• W4381377864 hasRelatedWork W2062091766 @default.
• W4381377864 hasRelatedWork W2348628890 @default.
• W4381377864 hasRelatedWork W2942045179 @default.
• W4381377864 hasRelatedWork W3011249866 @default.
• W4381377864 hasRelatedWork W3202203369 @default.
• W4381377864 hasRelatedWork W37072832 @default.
• W4381377864 hasRelatedWork W4362511091 @default.
• W4381377864 hasVolume "72" @default.
• W4381377864 isParatext "false" @default.
• W4381377864 isRetracted "false" @default.
• W4381377864 workType "article" @default.